BPC-157 Formal Reclassification Rule Expected Within Months as FDA Moves to Restore Compounding Access
After a February announcement by HHS Secretary Robert F. Kennedy Jr. that BPC-157 and 13 other peptides would be moved back to Category 1, the formal rulemaking process is now underway. Licensed compounding pharmacies are quietly preparing for restored access — but the window for the published rule remains uncertain.
Retatrutide Phase 2b Enrollment Underway — Final Results Expected Late 2026
Eli Lilly's triple receptor agonist continues to expand its clinical footprint after Phase 2 data showed up to 24% body weight reduction at 48 weeks — outpacing semaglutide and tirzepatide in head-to-head comparisons.
WADA Confirms TB-500 Remains on 2026 Prohibited List — No Appeal Window Until January
Athletes and coaches seeking clarity on Thymosin Beta-4 status will need to wait. WADA's annual list review process closes in September, with any changes effective January 2027.
503A vs. 503B: What the Compounding Distinction Means for Peptide Access Post-Reclassification
When BPC-157 moves back to Category 1, not all compounding pharmacies will be able to fill prescriptions. The difference between 503A and 503B facilities will matter enormously for patients and practitioners.
New PubMed Data: Retatrutide Outperforms GLP-1 Monotherapy in Insulin Sensitivity Markers
A secondary analysis of Phase 2 data published this week in The Lancet shows retatrutide's glucagon receptor activity drives metabolic improvements beyond what GLP-1 agonists alone can achieve.
Sikiric Lab Publishes New BPC-157 Angiogenesis Data in Peer-Reviewed Journal
The most prolific research group in peptide science has added to its substantial catalog with new evidence supporting BPC-157's mechanism in promoting new blood vessel formation in damaged tissue.
FDA's Bulk Drug Substances List: A Plain-Language Guide to Category 1 vs. Category 2 for Peptides
The regulatory framework governing compounded peptides confuses even experienced clinicians. Here is a straight-forward breakdown of what each category means and how the reclassification process works in practice.
Why Retatrutide May Be the Most Significant Obesity Drug Since Ozempic — and What That Means for Peptide Research
The triple agonist mechanism targets three separate metabolic pathways simultaneously. Independent endocrinologists say the 24% weight loss figure from Phase 2 is not an outlier — it may reflect a genuine ceiling-raiser for the field. What the data actually shows, stripped of industry framing.
The comparison to semaglutide is instructive: at equivalent timepoints, retatrutide produced roughly double the weight reduction. The mechanism difference — the addition of glucagon receptor agonism — appears to be the key driver.
The TB-500 Paradox: Widespread Community Use, Strong Animal Data, and Almost No Human Trials
Thymosin Beta-4 sits in an unusual position in the peptide landscape. Animal research is compelling across multiple tissue types. Community reports are overwhelmingly positive. Yet human pharmacokinetic data is nearly nonexistent. We examine what the evidence actually supports and where the gaps are.
The WADA prohibition adds another layer: athletes face career consequences for use, while non-athletes operate in a legal gray area that is entirely unaddressed by current regulation.
BPC-157
The most widely discussed compounding peptide in the regulatory gray zone. Tissue repair, gut healing, and tendon recovery research — alongside the evolving FDA reclassification story.
Retatrutide
The triple GIP/GLP-1/glucagon agonist from Eli Lilly. Phase 2 results surpassed expectations. Phase 2b enrollment is live. Everything you need to follow this compound intelligently.
TB-500 (Thymosin Beta-4)
Powerful regenerative properties backed by substantial animal research. Prohibited by WADA for athletes. Legal for non-athlete individuals. A nuanced status that demands careful reading.
BPC-157 Accelerates Achilles Tendon Healing via Upregulation of Growth Hormone Receptors: New Evidence from Rat Model
Sikiric et al. add to their body of work with tendon-specific data showing BPC-157's mechanism operating through GH receptor sensitization rather than direct anabolic action. The distinction matters clinically for understanding how and when to use the compound.
Retatrutide Phase 2 Secondary Analysis: Glucagon Receptor Contribution to Metabolic Improvement
The secondary analysis separates out the metabolic contribution of each receptor pathway, providing the clearest picture yet of why retatrutide outperforms dual agonists. Insulin sensitivity improvements appear driven primarily by the glucagon arm.
Thymosin Beta-4 Promotes Cardiac Muscle Repair in Post-Infarction Model: Implications for Human Applications
Cardiac research on TB-500 continues to expand beyond the musculoskeletal applications the compound is best known for in community circles. The cardiac data opens a separate clinical pathway that has received limited attention.
"Where do you legally source BPC-157 right now?" — Thread draws 600+ responses
The most upvoted thread of the month reflects the community's primary anxiety: with gray-market sellers facing increased scrutiny and compounding access not yet restored, many are struggling to find reliable legal sources. The thread has become an informal sourcing guide.
Community split on retatrutide: "research chemical" vs. "legitimate pharmaceutical pipeline"
An interesting debate has emerged over how to categorize retatrutide given that it is an active pharmaceutical in clinical trials, not a research chemical. Many community members are urging a distinction between peptides being actively developed by major pharma and gray-market research compounds.
TB-500 + BPC-157 stacking protocols under scrutiny as anecdotal reports accumulate
The most common community peptide stack — BPC-157 paired with TB-500 for injury recovery — has generated substantial anecdotal discussion. Experienced users note synergistic effects on chronic injuries, while researchers caution that no clinical data on the combination exists.